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Leukoplakia is the most common potentially malignant lesion of the oral cavity and can be categorised according to its
clinical appearance as homogeneous or nonhomogenous. Tobacco and areca nut use, either alone or in combination are the
most common risk factors for oral leukoplakia, but some oral leukoplakias are idiopathic. Some leukoplakias arise within
ﬁelds of precancerized oral epithelium in which the keratinocytes may be at diﬀerent stages of cytogenetic transformation.
Leukoplakiasmayunpredictablyregress,mayremainstable,ormayprogresstocarcinoma.Thereisagreaterriskofcarcinomatous
transformation of idiopathic leukoplakia, of non-homogenous leukoplakia, of leukoplakia aﬀecting the ﬂoor of the mouth; the
ventrolateral surface of the tongue and the maxillary retromolar and adjoining soft palate (collectively called high-risk sites),
of leukoplakia with high-grade epithelial dysplasia, and of leukoplakia in which the keratinocytes carry cytogenetic alterations
associated with carcinomatous transformation. Although there appears to be some link between human papillomavirus (HPV)
and oral leukoplakia, there is little evidence to support a causal relationship either between HPV infection and oral leukoplakia or
between HPV-infected leukoplakic keratinocytes and their carcinomatous transformation.
1.Introduction
Leukoplakia is the most common potentially malignant
lesion of the oral cavity [1, 2]. Leukoplakia is a term describ-
ing “a white lesion of the oral mucosa that cannot be char-
acterized clinically or microscopically as any other deﬁned
oral disease entity” [3, 4]. At a World Health Organisation
(WHO) workshop held in 2005, it was recommended that
oralleukoplakiabedeﬁnedas“awhiteplaqueofquestionable
riskhavingexcluded(other)knowndiseasesordisordersthat
carry no increased risk for cancer” [5–7]. Oral leukoplakia
needs to be distinguished from other predominantly white
keratotic lesions including frictional keratosis and stomatitis
nicotina, which do not have malignant potential [1, 2, 5–8].
About 70–90% of oral leukoplakias are related to smok-
ing and areca nut use, either alone or in combination, and
there is a direct relationship between the frequency and
the duration of cigarette, pipe, or cigar smoking and the
prevalence of oral leukoplakia [8, 9]. The factors implicated
in the pathogenesis of idiopathic leukoplakia are unknown.
However it is possible that infection of the oral epithe-
lium with human papillomavirus (HPV) and excessive
consumption of alcoholic beverages may be associated with
oral leukoplakia, but there is little evidence of a causal
relationship between either HPV infection or alcohol, and
oral leukoplakia [6].
It has been suggested that a deﬁnitive diagnosis of
oral leukoplakia must be established by histopathological
exclusion of other keratotic oral lesions that are recognised
asspeciﬁcentities,andbyexclusionofanyaetiologicalagents
other than tobacco/areca nut use [7].
It is the opinion of the authors that these criteria are
unrealistically limiting, ignoring as they do the possible
roles of HPV, alcohol, chronic inﬂammation, and low-
grade chronic frictional trauma in the pathogenesis of oral
leukoplakia. Referring to the WHO deﬁnition of 2005 above,
it is diﬃcult to understand how such a deﬁnition could
gain any useful currency since it is so “exclusive” that it
leaves no rational guidance for the everyday diagnosis of oral
leukoplakia.
2.Oral Leukoplakia: ClinicalAspects
According to its clinical appearance, oral leukoplakia can
be categorised into two main clinical types: homogeneous2 International Journal of Dentistry
and non-homogeneous. Either type may occur as an isolated
lesion or as multiple lesions. The leukoplakic lesion can vary
in size from a few millimetres to several centimeters [1, 2, 5–
12].
Homogeneous leukoplakia is a uniformly white ﬂat
plaque with a smooth or relatively smooth surface; non-
homogeneous leukoplakia may be nodular or verrucous
havingawrinkledorcorrugatedsurfaceormaybeamingling
of white and red areas termed erythroleukoplakia [7, 10, 11].
The clinical appearance of oral leukoplakia may change
overtime.Somehomogeneouslesionsmaybecomelarger,or
non-homogeneous, but most oral leukoplakias will remain
s t a b l eo rw i l lr e g r e s s ,w h i l es o m ef e ww i l lu n d e r g oc a r c i n o -
matous transformation [13–15].
Oral erythroplakia, of all precancerous oral lesions,
carries the greatest threat of malignant transformation. It
has a velvety-red appearance, and about 50% of all cases
of erythroplakia are already squamous cell carcinomata at
the time of diagnosis. The erythroplakic component of oral
erythroleukoplakia is identical to erythroplakia [16].
Proliferative verrucous leukoplakia, considered to be
either a clinical subtype of non-homogeneous oral leuko-
plakia or to be a distinct clinical entity, is not strongly associ-
ated with smoking, is characterized by multiple leukoplakic
lesions that aﬀect wide areas of the oral epithelium, and may
progress either to verrucous carcinoma or to squamous cell
carcinoma [17–20]. In most cases, proliferative verrucous
leukoplakia is recognised only late in its course since in its
initial stages it is identical to an isolated leukoplakia [17–24].
3. Epidemiology of OralLeukoplakia
The data from epidemiological studies on oral leukoplakia
is inconsistent, most probably owing to diﬀerences in case
selection criteria (house-to-house surveys, hospital surveys,
age, gender, race, ethnicity, and tobacco use) and in method-
ology (diagnostic criteria, time of follow-up and whether or
not the leukoplakia had previously been treated) [1, 10, 11].
Estimates of the global prevalence of oral leukoplakia
range from 0.5% to 3.46%, and of the rates of carcinomatous
transformation of oral leukoplakia from 0.7% to 2.9% [25].
Oral leukoplakia is more prevalent in India where persons
smoke and practice the habit of tobacco and areca nut
chewing more than elsewhere [26].
Oral leukoplakia is usually diagnosed in middle age, and
its prevalence increases with age. About 10% of oral leuko-
plakias are idiopathic and the greater part of the remaining
90% is associated with the use of tobacco/areca nut [26].
Males are more often aﬀected than females probably owing
to the greater prevalence of tobacco use by males [8]. The
buccal mucosa is aﬀected in 25% of cases, the mandibular
gingiva in 20%, the tongue in 10%, the ﬂoor of the mouth in
10%, and other oral sites account for the remainder [13].
The literature on the relationship between race and oral
leukoplakia is sparse. In a South African study of archived
histopathological material, 86% of oral leukoplakias were
from whites, 9% from blacks, and 5% from Asians, despite
the fact that the vast majority of South Africans are black
[27]. This is not easy to explain. Bearing in mind that the
study was on histopathological material, an explanation may
be that blacks tend to postpone seeking medical treatment
until the leukoplakia has already undergone carcinomatous
transformation, thus skewing the statistics away from the
leukoplakia [27], or because black people in South Africa
may smoke less than white people.
4.EpithelialDysplasiaandOral Leukoplakia
The reported prevalence of epithelial dysplasia in oral leuko-
plakiarangesfrom5%to25%[8].Dysplasiaismorefrequent
in non-homogeneous than in homogeneous leukoplakia
[11], and it is probable that dysplasia is the histopathological
expression of genomic and molecular alterations in a ﬁeld of
keratinocytes [28, 29].
The presence of epithelial dysplasia is a marker of the
malignant potential of oral leukoplakia, and the risk of
an individual leukoplakic lesion to progress to carcinoma
increases with the increase of the grade of the epithelial
dysplasia [11, 12, 14, 30].
However, some dysplastic oral leukoplakias can remain
stable or even regress, while some oral leukoplakias without
epithelial dysplasia will indeed progress to carcinoma [5,
11, 12]. In one study 36% of dysplastic oral leukoplakias
progressed to squamous cell carcinoma, but a substantial
proportion of 16% of oral leukoplakias without epithelial
dysplasia at the time of initial biopsy also progressed to
carcinoma [31]. The risk of progression to carcinoma of
leukoplakias with moderate and severe dysplasia is estimated
to be twice as great as for oral leukoplakias with simple
epithelial hyperplasia or with mild dysplasia [14].
Treatment of dysplastic oral leukoplakia by excision, by
laser or by cryosurgery, or by topical or systemic chemo-
therapy does not eliminate either the risk of relapse or
recurrence, or the risk of carcinomatous transformation
[1, 5, 6]. The estimated recurrence rate of oral leukoplakia
m a yb ea sh i g ha s3 0 %[ 32], and squamous cell carcinoma
developsat12%ofsitesoftreatedleukoplakia[15].Inastudy
investigating the pattern of carcinomatous transformation of
oral leukoplakia and oral erythroplakia, 36% of carcinomata
developed at the same site, 49% at contiguous sites, and 15%
at oral sites remote from the preexisting lesions [33].
It is evident from this data that some cases of treated
oral leukoplakia are unpredictably destined to recur or
to undergo carcinomatous transformation, and that there
are not yet any diagnostic methods available (clinical,
histological or molecular), to conﬁdently identify these cases
[1].
Epithelial dysplasia in oral leukoplakia is a useful marker
oftheriskofcarcinomatoustransformationandisanimpor-
tant guide to clinical management [1, 11, 28]. However, since
dysplasia can remain stable for long periods, it cannot be
used with conﬁdence as a predictor of carcinomatous trans-
formation [14, 29]. Moreover, as the histological exercise of
grading of epithelial dysplasia is highly subjective with low
interpersonal and intrapersonal reproducibility [16, 34, 35],
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entirelesion[34,36],ahistopathologicalreportofanydegree
of epithelial dysplasia or of the absence of epithelial dysplasia
must be viewed with caution.
5.The NaturalCourse andthe Malignant
PotentialofOral Leukoplakia
The progression of oral leukoplakia to carcinoma is unpre-
dictable but is relatively infrequent with an estimated overall
risk of less than 2% per year [5, 6, 13, 26]; if progression
occurs, it may take a few months or many years [8]. The
carcinomatous transformation of oral leukoplakia is not
predictably associated with tobacco smoking [33], and the
frequency of carcinomatous transformation of idiopathic
leukoplakia is higher than that of tobacco-associated leuko-
plakia [11, 26].
In populations where smoking, the use of smokeless
tobacco, reverse smoking, and the use of areca nut are
very prevalent, most squamous cell carcinomata arise from
preexisting leukoplakias; while in populations with a lower
prevalence of these habits, most squamous cell carcinomata
arise de novo in normal-looking epithelium [26]. It has
been suggested that squamous cell carcinoma arising de
novo usually runs a more aggressive course and has a less
favourable prognosis than squamous cell carcinoma arising
from preexisting leukoplakia [12, 26], but a recent study
hasdemonstratedlittlediﬀerence[37].Sometimessquamous
cell carcinoma arises de novo in close proximity to oral
leukoplakias [8].
Non-homogeneous leukoplakia has a greater risk of car-
cinomatous transformation (20–25%) than homogeneous
leukoplakia (0.6–5%) [11, 13]. Most leukoplakias either
remainstableorwillregress[13,15].However,ifproliferative
verrucous leukoplakia is considered as a distinct entity, most
such cases progress to carcinoma [18, 24].
The rates of progression of large oral leukoplakias
(>5mm) and of leukoplakias at sites in the mouth known
to be at most risk of developing carcinoma (ﬂoor of
mouth, ventrolateral surface of tongue, and maxillary
retromolar/soft palate region) are greater than for smaller
leukoplakias or for leukoplakias at other sites in the mouth
[1, 11, 13, 33, 38]. The increased risk of carcinomatous
transformation of oral leukoplakia at high-risk sites is not
entirely a function of the degree of dysplasia. It is also
d e p e n d e n tu p o na sy e tu n d e ﬁ n e dc h a r a c t e r i s t i c so ft h e
location of the leukoplakia since the rate of carcinomatous
transformation of dysplastic leukoplakias at high-risk sites is
greater than the rate of transformation of equally dysplastic
leukoplakias at other sites [38].
There is evidence that clearly suggests that some leuko-
plakias arise from cytogenetically altered transformed ker-
atinocytes within ﬁelds of precancerized oral epithelium.
Keratinocytes of oral leukoplakia show cytogenetic changes
including alterations in the p53 tumour suppressor gene,
aberrations in their DNA content, and loss of heterozy-
gosity (LoH) at chromosomal regions of candidate tumour
suppressor genes [20, 33, 39–45] .L o Ha te i t h e r3 po ra t
9p occurs frequently in keratinocytes of oral leukoplakia
and is associated with carcinomatous transformation of
these lesions [33, 41, 42, 44, 45]. Additional cytogenetic
alterations to the keratinocytes in the precancerized ﬁeld
referred to above may result in the evolution of one or
severalkeratinocytescontainingacompletesetofcytogenetic
alterations of a cancerous phenotype, and in the subsequent
development of squamous cell carcinoma [41, 46, 47].
However, some precancerous oral leukoplakias in which
cytogenetic alterations in the keratinocytes cannot be
demonstrated, nevertheless undergo carcinomatous trans-
formation [41, 42]. The pathogenic mechanisms that bring
about the progressive transformation of these keratinocytes
to carcinomatous cells are yet to be elucidated. Most oral
leukoplakias are benign in nature and will remain stable
or will regress [28, 32]. These leukoplakias probably have
ad i ﬀerent aetiopathogenesis to precancerous leukoplakias
and probably do not have the cytogenetic characteristics of
precancerous leukoplakias. What is certain, however, is that
leukoplakias with malignant potential and those without
malignant potential cannot be distinguished clinically [1].
6. HumanPapillomavirusandOralLeukoplakia
Human papilloma viruses (HPVs) are strictly epitheliotropic
and infect either cutaneous or mucosal squamous epithe-
lium, depending upon their genotype [48, 49]. Those that
infect mucosal epithelium have been categorized into high-
risk types (e.g., HPV-16, 18, 31, 33, and 35) based on their
epidemiological association with carcinoma of the cervix
uteri, or into low-risk types (HPV-6, 11, 13, and 32) [50].
These categories have been universally adopted for use in
studies of the oncogenic signiﬁcance of HPV infection at all
anatomical regions of the upper aerodigestive tract.
Low-risk HPV genotypes have been implicated in the
pathogenesis of the benign oral proliferative epithelial
lesions, squamous cell papilloma, common wart (verru-
cous vulgaris), condyloma acuminatum, and focal epithe-
lial hyperplasia (Heck disease); while high-risk types have
been associated with precancerous and cancerous oral and
oropharyngeal epithelial lesions [49, 51–56].
There is an extreme variation in the reported prevalence
of HPV infection in oral precancerous and cancerous lesions
ranging from 0% to 100% [57, 58]. This is owing to
diﬀerences in sampling and HPV detection methods, to
diﬀerencesinethnicity,geographiclocations,andsamplesize
of the subjects examined, and to the inappropriate group-
ing together of diﬀerent lesions from diﬀerent anatomical
locations of the mucosa of the upper aerodigestive tract
[49, 51, 58–64].
Many studies investigating the association of HPV and
squamous cell carcinoma of the mucosa of the upper
aerodigestive tract used PCR techniques for detection of
HPV DNA without also quantifying the DNA viral load.
PCR can detect extremely small fragments of DNA that may
represent either contamination of the sample or biologically
insigniﬁcant HPV infection [51, 57, 58]. These ﬁndings have
been reported as if they were pathogenically signiﬁcant.4 International Journal of Dentistry
Whether these are legitimate ﬁndings or are the results
of inconsistencies and errors in methodology, several HPV
genotypes have been detected in precancerous oral lesions.
High-risk HPV genotypes, in particular HPV-16, have been
reported to be the most prevalent in oral leukoplakias,
including proliferative verrucous leukoplakia [55, 65]. Other
reports implicated low-risk rather than high-risk HPV
genotypes in oral leukoplakia [54, 63], and yet others assert
that oral leukoplakia is coinfected with a variety of HPV
genotypes [49, 55, 66]. In a meta-analysis of data from 94
studies of a total of 4580 specimens, Miller and Johnstone
[63] determined that the likelihood of HPV being detected
in precancerous oral lesions is 2 to 3 times greater and in
oral squamous cell carcinoma is 4 to 5 times greater than
in normal oral mucosa. The prevalence of HPV in normal
oral mucosa, in nondysplastic leukoplakias, in dysplastic
leukoplakias and in other precancerous intraepithelial oral
neoplasms, and in oral squamous cell carcinoma is likely to
be 10%, 20.2%, 26.2%, and 46.5%, respectively [63].
This suggests that there may be some link between HPV
infection and oral precancerous and cancerous lesions. As
E6 and E7 oncoproteins of high-risk HPV genotypes have
the capacity to mediate carcinomatous transformation of
infected keratinocytes by inactivating cellular p53 and Rb
tumour suppressor pathways [50, 52], HPV may play either
an oncogenic or a co-oncogenic role in some HPV-infected
precancerous and cancerous epithelial neoplasms.
In fact, HPV-16 has been found to be causally associated
primarily with squamous cell carcinoma of the palatal tonsils
[67–70] in a subset of subjects who are younger, consume
less tobacco, are more engaged in high-risk sexual behaviour
(great number of lifetime sexual partners and practicing
oral-genital sex), have higher HPV-16 serum antibody titers,
and have a better disease-free survival and overall survival
rates than subjects with HPV-cytonegative oropharyngeal
squamous cell carcinoma [51, 64, 67–70]. The cells of HPV-
cytopositive oropharyngeal carcinoma in these subjects have
a distinct molecular proﬁle [50]. The cells of squamous
cell carcinoma causally associated with HPV express E6/E7
oncoproteins. They frequently demonstrate viral integration
within the cellular genome with the presence of intact
E6 gene. They exhibit high viral load, reduced expression
of Rb proteins, functional overexpression of p16 INK4A,
unmutated p53 gene, and loss of heterozygosity (LoH) at
chromosomal loci 3p, 9p and 17p is infrequent [51, 68–
74].Incontrast,HPV-cytonegativeoropharyngealsquamous
cell carcinoma is characterized by p53 gene mutations, by
frequent LoH at 3p, 9p, and 17p, by decreased levels of
p16INK4A and by normal or increased levels of Rb proteins
[50, 51, 71].
Recent meta-analyses and comprehensive studies [60, 62,
67, 75] show little or no causal association between HPV
and oral squamous cell carcinoma in contrast to the strong
association between HPV and oropharyngeal squamous cell
c a r c i n o m a .H P V - 1 6c y t o p o s i t i v eo r a ls q u a m o u sc e l lc a r c i -
noma is characterized by a low viral load, by infrequent viral
integration, and the cancerous cells seldom contain active
transcriptional E6/E7 mRNA [72, 76]. However, it is possible
that, in HPV-cytopositive oral squamous cell carcinomata
that do not express E6/E7 mRNA, E6/E7 oncoproteins may
well have participated or have had a complementary role in
the initial transformation, but then phased out [77].
With oropharyngeal carcinoma as the model, a causal
association between HPV and cancerization in oral epithe-
lium is likely if the cells of the lesion contain HPV DNA
expressing E6 and/or E7 mRNA [71], if there is viral
integration within the cellular genome [74], and if there is
a high viral load (>1 copies per cell). A limited biological
signiﬁcance of the virus in the process of transformation
can be deduced if there is a low-copy number (<1c o p yp e r
cell), or if there is no transcriptional activity of E6 and/or
E7 mRNA [60, 71]. Nevertheless, although integration of
HPV DNA into the cellular genome is a strong indication of
the oncogenic potential of the virus, transcription of HPV-
16 E6/E7 mRNA has been shown to occur in oropharyngeal
carcinoma without integration of viral DNA, the virus being
in an episomal form [69].
It is well established that non-homogeneous leukoplakias
more frequently undergo malignant transformation than
homogeneous leukoplakias, yet it appears that HPV is
found more commonly in homogeneous than in non-
homogeneous leukoplakia [54, 78]. Nevertheless the role
of HPV in the pathogenesis of oral leukoplakia and in its
progression to carcinoma is unclear since there is a low viral
load in HPV-cytopositive precancerous and cancerous oral
lesions, and viral integration is seldom found [72, 76]. It
is possible that HPV DNA in oral leukoplakia and in oral
squamouscellcarcinomamaybeoncogenicallyinsigniﬁcant.
Alternatively the HPV may have superinfected keratinocytes
already initially transformed and may thus additively or
synergisticallypromotelaterstagesoftransformation[49,51,
69].
Little is known about the E6 and E7 proteins of low-
risk HPV either with regard to their role in the patho-
genesis of HPV-infected oral leukoplakias, or with regard
to their role in the carcinomatous transformation of some
leukoplakias. It is possible that as in other HPV-associated
benignproliferativeoralepitheliallesions,E6andE7proteins
of low-risk HPV types found in oral leukoplakia may
stimulate suprabasal postmitotic infected keratinocytes to
reenter the S-phase of the cell cycle resulting in epithelial
proliferation and disturbed maturation, without causing the
genomic instability possibly associated with subsequent cell
transformation.Thismechanismmaybeaco-determinantof
the development of the leukoplakia, but there is no concrete
evidence to support this.
7. Treatment
As oral leukoplakia is potentially malignant, and as some
leukoplakias will unpredictably progress to carcinoma, ide-
ally all oral leukoplakias should be treated. When dealing
with two or three accessible circumscribed lesions, the treat-
ment of choice is surgical excision. For multiple or for large
leukoplakias where surgical treatment would be impractical
because it would result in unacceptable deformities or in
functional disabilities, treatment can be by cryosurgery,International Journal of Dentistry 5
laser surgery, or by the use of topical bleomycin. However,
regardless of the extent of the lesion or of the modality of
treatment, in as many as 30% of treated cases, leukoplakias
will recur and treatment will not prevent the progression of
some leukoplakias to squamous cell carcinoma [5, 15, 21,
32].
Idiopathic leukoplakia, non-homogeneous leukoplakia,
leukoplakia aﬀecting high-risk oral sites, and leukoplakia
showing moderate or severe grades of epithelial dysplasia
and particularly leukoplakias, in which a combination of
thesefactorsaﬀectthe risk ofcarcinomatous transformation,
should be treated aggressively. Any changes in colour, texture
orsize,andappearanceofadditionalleukoplakiasatneworal
sites are advance warning of the possibility of carcinomatous
transformation.
8. Summary
Leukoplakia is the most common potentially malignant
lesion of the mouth. It may unpredictably regress, may
remain stable, or may undergo carcinomatous transforma-
tion. Those leukoplakias that are committed to a cancerous
pathway most probably arise within a ﬁeld of precancerized
epithelium consisting of keratinocytes at diﬀerent stages of
cytogenetic transformation. This may explain the high rate
of recurrence of oral leukoplakia despite treatment, and why
some leukoplakias progress to carcinoma.
Many studies have reported the presence of HPV DNA
in oral leukoplakias. However, there is not enough evidence
to prove any casual association either between HPV and the
development of oral leukoplakia, or between HPV and the
progression of oral leukoplakia to carcinoma. The nature of
the link between HPV infection and oral leukoplakia is as yet
unknown.
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